Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 1;10(5):1130-1139.
doi: 10.14336/AD.2019.0112. eCollection 2019 Oct.

Subtyping of Parkinson's Disease - Where Are We Up To?

Affiliations
Review

Subtyping of Parkinson's Disease - Where Are We Up To?

Elizabeth Qian et al. Aging Dis. .

Abstract

Heterogenous clinical presentations of Parkinson's disease have aroused several attempts in its subtyping for the purpose of strategic implementation of treatment in order to maximise therapeutic effects. Apart from a priori classifications based purely on motor features, cluster analysis studies have achieved little success in receiving widespread adoption. A priori classifications demonstrate that their chosen factors, whether it be age or certain motor symptoms, do have an influence on subtypes. However, the cluster analysis approach is able to integrate these factors and other clinical features to produce subtypes. Differences in inclusion criteria from datasets, in variable selection and in methodology between cluster analysis studies have made it difficult to compare the subtypes. This has impeded such subtypes from clinical applications. This review analysed existing subtypes of Parkinson's disease, and suggested that future research should aim to discover subtypes that are robustly replicable across multiple datasets rather than focussing on one dataset at a time. Hopefully, through clinical applicable subtyping of Parkinson's disease would lead to translation of these subtypes into research and clinical use.

Keywords: Parkinson’s disease; heterogenous; subtypes; translation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Summary of PD Subtyping. The flowchart demonstrated although the two subtyping approaches had different starting points, a common pathway of biological validation, prognosis evaluation, and the destinations (desired outcomes) was followed.

References

    1. Mizuno Y (2007). Where do we stand in the treatment of Parkinson's disease? J Neurol, 254:13-18.
    1. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. (2016). Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388:1545-1602. - PMC - PubMed
    1. Williams-Gray CH, Barker RA (2017). Parkinson disease: Defining PD subtypes - a step toward personalized management? Nat Rev Neurol, 13:454-455. - PubMed
    1. von Coelln R, Shulman LM (2016). Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease. Curr Opin Neurol, 29:727-734. - PubMed
    1. Foltynie T, Brayne C, Barker RA (2002). The heterogeneity of idiopathic parkinson's disease. J Neurol, 249:138-145. - PubMed

LinkOut - more resources